Chris Degnan - Oct 8, 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Oct 8, 2024
Transactions value $
$0
Form type
4
Date filed
10/9/2024, 04:22 PM
Previous filing
Mar 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Award $0 +13.5K $0.00 13.5K Oct 8, 2024 Ordinary Shares 13.5K Direct F1, F2
transaction URGN Employee Stock Option (right to buy) Award $0 +74.1K $0.00 74.1K Oct 8, 2024 Ordinary Shares 74.1K $13.11 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 1/3 of the shares underlying the restricted stock units will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027.
F3 1/3 of the shares underlying the stock option will vest on each of October 8, 2025, October 8, 2026 and October 8, 2027.